Nancy Gavert

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7965849/publications.pdf

Version: 2024-02-01

40 papers	4,727 citations	236925 25 h-index	289244 40 g-index
40 all docs	40 docs citations	40 times ranked	6284 citing authors

#	Article	IF	Citations
1	Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer. Nature Cancer, 2022, 3, 219-231.	13.2	24
2	A Necessary Role for Increased Biglycan Expression during L1-Mediated Colon Cancer Progression. International Journal of Molecular Sciences, 2022, 23, 445.	4.1	5
3	The Collagen-Modifying Enzyme PLOD2 Is Induced and Required during L1-Mediated Colon Cancer Progression. International Journal of Molecular Sciences, 2021, 22, 3552.	4.1	16
4	IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy. Nature Cancer, 2021, 2, 1055-1070.	13.2	9
5	Deep microbial analysis of multiple placentas shows no evidence for a placental microbiome. BJOG: an International Journal of Obstetrics and Gynaecology, 2020, 127, 159-169.	2.3	94
6	The human tumor microbiome is composed of tumor typeâ€“specific intracellular bacteria. Science, 2020, 368, 973-980.	12.6	1,077
7	Recent insights into the role of <scp>L1CAM</scp> in cancer initiation and progression. International Journal of Cancer, 2020, 147, 3292-3296.	5.1	17
8	Predicting and affecting response to cancer therapy based on pathway-level biomarkers. Nature Communications, 2020, 11, 3296.	12.8	55
9	Increased expression of cathepsin D is required for L1-mediated colon cancer progression. Oncotarget, 2019, 10, 5217-5228.	1.8	21
10	ISG15 induction is required during L1-mediated colon cancer progression and metastasis. Oncotarget, 2019, 10, 7122-7131.	1.8	10
11	Ev vivo organ culture as potential prioritization tool for breast cancer targeted therapy. Cancer Biology and Therapy, 2018, 19, 645-648.	3.4	9
12	The intestinal stem cell regulating gene ASCL2 is required for L1-mediated colon cancer progression. Cancer Letters, 2018, 424, 9-18.	7.2	20
13	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science, 2017, 357, 1156-1160.	12.6	1,059
14	A point mutation in the extracellular domain of L1 blocks its capacity to confer metastasis in colon cancer cells via CD10. Oncogene, 2017, 36, 1597-1606.	5.9	15
15	The Wnt Target Gene L1 in Colon Cancer Invasion and Metastasis. Cancers, 2016, 8, 48.	3.7	12
16	Induction of the intestinal stem cell signature gene SMOC-2 is required for L1-mediated colon cancer progression. Oncogene, 2016, 35, 549-557.	5.9	50
17	Clusterin, a gene enriched in intestinal stem cells, is required for L1-mediated colon cancer metastasis. Oncotarget, 2015, 6, 34389-34401.	1.8	42
18	The lipid-transfer protein Nir2 enhances epithelial-mesenchymal transition and facilitates breast cancer metastasis. Journal of Cell Science, 2014, 127, 4740-9.	2.0	32

#	Article	IF	Citations
19	c-Kit Is Suppressed in Human Colon Cancer Tissue and Contributes to L1-Mediated Metastasis. Cancer Research, 2013, 73, 5754-5763.	0.9	32
20	The phosphatidylinositolâ€transfer protein Nir2 binds phosphatidic acid and positively regulates phosphoinositide signalling. EMBO Reports, 2013, 14, 891-899.	4.5	111
21	Global analysis of L1-transcriptomes identified IGFBP-2 as a target of ezrin and NF-ÎºB signaling that promotes colon cancer progression. Oncogene, 2013, 32, 3220-3230.	5.9	42
22	L1-Mediated Colon Cancer Cell Metastasis Does Not Require Changes in EMT and Cancer Stem Cell Markers. Molecular Cancer Research, 2011, 9, 14-24.	3.4	51
23	Nuclear factor-ÎºB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. Journal of Cell Science, 2010, 123, 2135-2143.	2.0	89
24	Coordinating changes in cell adhesion and phenotype during EMT-like processes in cancer. F1000 Biology Reports, 2010, 2, 86.	4.0	6
25	The cell adhesion nectinâ€like molecules (Necl) 1 and 4 suppress the growth and tumorigenic ability of colon cancer cells. Journal of Cellular Biochemistry, 2009, 108, 326-336.	2.6	41
26	L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Letters, 2009, 282, 137-145.	7.2	114
27	L1-CAM in cancerous tissues. Expert Opinion on Biological Therapy, 2008, 8, 1749-1757.	3.1	76
28	Epithelialâ€“mesenchymal transition and the invasive potential of tumors. Trends in Molecular Medicine, 2008, 14, 199-209.	6.7	304
29	Laparoscopic Adjustable Gastric Banding Surgery for Morbid Obesity: Imaging of Normal Anatomic Features and Postoperative Gastrointestinal Complications. American Journal of Roentgenology, 2007, 188, 472-479.	2.2	46
30	Expression of L1-CAM and ADAM10 in Human Colon Cancer Cells Induces Metastasis. Cancer Research, 2007, 67, 7703-7712.	0.9	186
31	Fascin, a Novel Target of Î²-Catenin-TCF Signaling, Is Expressed at the Invasive Front of Human Colon Cancer. Cancer Research, 2007, 67, 6844-6853.	0.9	249
32	Î²â€Catenin signaling in biological control and cancer. Journal of Cellular Biochemistry, 2007, 102, 820-828.	2.6	155
33	L1, a novel target of Î²-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. Journal of Cell Biology, 2005, 168, 633-642.	5.2	335
34	The Shed Ectodomain of Nr-CAM Stimulates Cell Proliferation and Motility, and Confers Cell Transformation. Cancer Research, 2005, 65, 11605-11612.	0.9	49
35	Safety and feasibility of revisional laparoscopic surgery for morbid obesity: conversion of open silastic vertical banded gastroplasty to laparoscopic adjustable gastric banding. Surgical Endoscopy and Other Interventional Techniques, 2004, 18, 203-206.	2.4	18
36	Laparoscopic Revisional Surgery for Life-Threatening Stenosis Following Vertical Banded Gastroplasty, Together with Placement of an Adjustable Gastric Band. Obesity Surgery, 2003, 13, 399-403.	2.1	15

#	Article	IF	Citations
37	The clinical spectrum of band erosion following laparoscopic adjustable silicone gastric banding for morbid obesity. Surgical Endoscopy and Other Interventional Techniques, 2003, 17, 861-863.	2.4	96
38	Bariatric surgery in adolescence. Journal of Pediatric Surgery, 2003, 38, 1379-1382.	1.6	97
39	Molecular analysis of the APC gene in 71 Israeli families: 17 novel mutations. Human Mutation, 2002, 19, 664-664.	2.5	35
40	Apolipoprotein-E Genotype and the Risk of Developing Cholelithiasis following Bariatric Surgery: a Clue to Prevention of Routine Prophylactic Cholecystectomy. Obesity Surgery, 2002, 12, 354-357.	2.1	13